Recombinant human VEGF Receptor 2 protein (Active) (ab106310)
Key features and details
- Expression system: Insect cells
- Purity: > 95% SDS-PAGE
- Active: Yes
- Suitable for: Functional Studies, SDS-PAGE
-
Product name
Recombinant human VEGF Receptor 2 protein (Active)
See all VEGF Receptor 2 proteins and peptides -
Biological activity
Measured by its ability to inhibit the VEGF165-induced proliferation in human umbilical vein endothelial (HUVE) cells.
-
Purity
> 95 % SDS-PAGE. -
Expression system
Insect cells -
Accession
-
Protein length
Full length protein -
Animal free
No -
Nature
Recombinant -
-
Species
Human -
Sequence
The soluble receptor protein consists of the first 6 extracellular domains and contains the unique C-terminal end of native Human soluble VEGF Receptor 2 (CGRETILDHSAEAVGMP) [Albuquerque et al.,Nature Medicine,2009] generated by alternative splicing. -
Predicted molecular weight
105 kDa
-
Preparation and Storage
-
Alternative names
- CD309
- CD309 antigen
- EC 2.7.10.1
see all -
Function
Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. -
Involvement in disease
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. -
Cellular localization
Membrane. - Information by UniProt
Images
-
Inhibition of the VEGF165-induced proliferation in HUVECs by soluble VEGFR-2/KDR. VEGF165 (10ng/ml) was preincubated with increasing amounts of sVEGFR-2/KDR for 1h and then added to the cells.
-
Inhibition of the VEGF165-induced proliferation of HUVE cells by recombinant human and mouse endogenous sKDR and sFlk-1 HUVECs were stimulated with 10 ng/ml VEGF165, both soluble receptors were added with a 100X excess.
-
SDS-PAGE showing ab106310